PA8505201A1 - Aminoacidos biciclicos como agentes farmaceuticos - Google Patents

Aminoacidos biciclicos como agentes farmaceuticos

Info

Publication number
PA8505201A1
PA8505201A1 PA20008505201A PA8505201A PA8505201A1 PA 8505201 A1 PA8505201 A1 PA 8505201A1 PA 20008505201 A PA20008505201 A PA 20008505201A PA 8505201 A PA8505201 A PA 8505201A PA 8505201 A1 PA8505201 A1 PA 8505201A1
Authority
PA
Panama
Prior art keywords
amino acids
bicycle
pharmaceutical agents
novedous
drugs
Prior art date
Application number
PA20008505201A
Other languages
English (en)
Spanish (es)
Inventor
Justin Stephen Bryans
David Clive Blakemore
Simon Osborne
Jean-Marie Receveur
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PA8505201A1 publication Critical patent/PA8505201A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/20—All rings being cycloaliphatic the ring system containing seven carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/22—All rings being cycloaliphatic the ring system containing eight carbon atoms, e.g. pentalene
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/24—All rings being cycloaliphatic the ring system containing nine carbon atoms, e.g. perhydroindane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
    • C07C2602/28—Hydrogenated naphthalenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
PA20008505201A 1999-10-20 2000-10-18 Aminoacidos biciclicos como agentes farmaceuticos PA8505201A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16072599P 1999-10-20 1999-10-20

Publications (1)

Publication Number Publication Date
PA8505201A1 true PA8505201A1 (es) 2002-08-29

Family

ID=22578159

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20008505201A PA8505201A1 (es) 1999-10-20 2000-10-18 Aminoacidos biciclicos como agentes farmaceuticos

Country Status (50)

Country Link
US (2) US6689906B1 (enExample)
EP (2) EP1226110B1 (enExample)
JP (2) JP3632191B2 (enExample)
KR (2) KR100593349B1 (enExample)
CN (1) CN1165518C (enExample)
AP (2) AP2004003186A0 (enExample)
AR (2) AR026087A1 (enExample)
AT (2) ATE293590T1 (enExample)
AU (2) AU778871B2 (enExample)
BG (2) BG108860A (enExample)
BR (1) BR0014972B1 (enExample)
CA (1) CA2386297C (enExample)
CO (1) CO5280060A1 (enExample)
CR (1) CR6620A (enExample)
CU (1) CU23112A3 (enExample)
CZ (1) CZ295960B6 (enExample)
DE (2) DE60019628T2 (enExample)
DO (1) DOP2000000083A (enExample)
DZ (1) DZ3197A1 (enExample)
EA (1) EA005206B1 (enExample)
EC (1) ECSP045393A (enExample)
EE (1) EE200200211A (enExample)
ES (2) ES2237464T3 (enExample)
GE (1) GEP20043297B (enExample)
GT (2) GT200000183A (enExample)
HK (1) HK1049826B (enExample)
HN (1) HN2000000224A (enExample)
HR (2) HRP20020428B1 (enExample)
HU (1) HUP0203325A3 (enExample)
IL (3) IL149143A0 (enExample)
IS (2) IS6348A (enExample)
MA (1) MA26842A1 (enExample)
MX (1) MXPA02003229A (enExample)
MY (1) MY127678A (enExample)
NO (2) NO20021780L (enExample)
NZ (1) NZ517961A (enExample)
OA (1) OA12070A (enExample)
PA (1) PA8505201A1 (enExample)
PE (1) PE20010740A1 (enExample)
PL (1) PL354607A1 (enExample)
PT (1) PT1226110E (enExample)
SI (1) SI1226110T1 (enExample)
SK (1) SK5232002A3 (enExample)
SV (1) SV2001000188A (enExample)
TR (2) TR200201094T2 (enExample)
TW (2) TW200505824A (enExample)
UA (1) UA72931C2 (enExample)
WO (1) WO2001028978A1 (enExample)
YU (2) YU29302A (enExample)
ZA (1) ZA200202543B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7164034B2 (en) 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
ATE390133T1 (de) * 2000-06-26 2008-04-15 Warner Lambert Co Gabapentinanaloga für schlafstörungen
US6620829B2 (en) 2000-10-17 2003-09-16 Warner-Lambert Company Method of treating noninflammatory cartilage damage
EP1226820A1 (en) * 2001-01-26 2002-07-31 Warner-Lambert Company Use of bicyclic amino acids for preventing and treating visceral pain and gastrointestinal disorders
WO2002085839A1 (en) 2001-04-19 2002-10-31 Warner-Lambert Company Llc Fused bicyclic or tricyclic amino acids
GB2375109A (en) * 2001-05-04 2002-11-06 Warner Lambert Co Process for preparing bicyclic amino acid
GB2375108A (en) * 2001-05-04 2002-11-06 Warner Lambert Co Production of a bicycloheptanone
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
MXPA03011566A (es) * 2001-06-11 2004-10-28 Xenoport Inc Formas de dosificacion de profarmacos de analogos de gaba administrados oralmente que tienen toxicidad reducida.
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
EP1469841A1 (en) * 2002-01-31 2004-10-27 Warner-Lambert Company Alpha 2 delta ligands to treat tinnitus
PL372210A1 (en) * 2002-02-22 2005-07-11 Warner-Lambert Company Llc Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2
EP1515709A2 (en) * 2002-06-27 2005-03-23 Warner-Lambert Company LLC Use of an alpha2delta ligand such as gabapentin or pregabalin for treating attention deficit hyperactivity disorder
JP2005539092A (ja) * 2002-08-15 2005-12-22 ファイザー・インク 縮合二環式または三環式アミノ酸の治療における使用
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
GB0219024D0 (en) * 2002-08-15 2002-09-25 Pfizer Ltd Synergistic combinations
GB0223072D0 (en) 2002-10-04 2002-11-13 Pfizer Ltd Cyclic nitromethyl acetic acid derivatives
US7018818B2 (en) 2002-10-04 2006-03-28 Pfizer Inc. Intermediates in the preparation of therapeutic fused bicyclic amino acids
US7060727B2 (en) 2002-12-11 2006-06-13 Xenoport, Inc. Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof
DE60332387D1 (de) 2002-12-13 2010-06-10 Warner Lambert Co Alpha-2-delta-ligand zur behandlung vonsymptomen der unteren harnwege
CN101862317A (zh) 2002-12-13 2010-10-20 沃尼尔·朗伯有限责任公司 用于治疗纤维肌痛和其它疾病的普加巴林衍生物
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
DE602004024317D1 (de) 2003-09-12 2010-01-07 Pfizer Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern
WO2006092692A1 (en) * 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
AR061728A1 (es) * 2006-06-30 2008-09-17 Pfizer Prod Inc Composicion para tratamiento usando compuestos selectivos alfa-2-delta-1
ATE511860T1 (de) 2006-12-22 2011-06-15 Recordati Ireland Ltd Kombinationstherapie für erkrankungen der unteren harnwege mit 2 liganden und nsar
KR101409079B1 (ko) 2007-09-28 2014-06-18 다이이찌 산쿄 가부시키가이샤 2 고리성 γ-아미노산 유도체
KR101674700B1 (ko) * 2009-03-26 2016-11-09 다이이찌 산쿄 가부시키가이샤 2고리성 γ-아미노산 유도체의 제조 방법
WO2012169475A1 (ja) 2011-06-08 2012-12-13 第一三共株式会社 クライゼン転位反応による二環性化合物の製造方法
EP2719676B1 (en) 2011-06-08 2017-12-13 Daiichi Sankyo Company, Limited Method for producing bicyclic compound via iminium salt
ES2686929T3 (es) 2011-12-15 2018-10-22 Daiichi Sankyo Company, Limited Procedimiento de resolución óptica para compuesto bicíclico utilizando catalizador asimétrico
KR101976891B1 (ko) 2012-04-10 2019-05-09 다이이찌 산쿄 가부시키가이샤 효소를 사용하는 2 고리성 화합물의 광학 분할 방법
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
TWI635071B (zh) 2013-07-08 2018-09-11 第一三共股份有限公司 光學活性二環γ－胺基酸衍生物及其製造方法
WO2018166855A1 (en) 2017-03-16 2018-09-20 Basf Se Heterobicyclic substituted dihydroisoxazoles
CN113045410A (zh) * 2021-03-29 2021-06-29 华东理工大学 一种双环降二萜类化合物及其合成基因及制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3641129A (en) * 1969-06-17 1972-02-08 Merck & Co Inc Antifibrinolytic compounds
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
KR100589066B1 (ko) 1997-10-27 2006-06-13 워너-램버트 캄파니 엘엘씨 약제로서 유용한 시클릭 아미노산 및 그의 유도체

Also Published As

Publication number Publication date
AR045456A2 (es) 2005-10-26
TR200201094T2 (tr) 2002-09-23
YU73004A (sh) 2005-11-28
PL354607A1 (en) 2004-01-26
MA26842A1 (fr) 2004-12-20
JP2003512348A (ja) 2003-04-02
TW200505824A (en) 2005-02-16
DZ3197A1 (fr) 2001-04-26
JP3744928B2 (ja) 2006-02-15
CN1382118A (zh) 2002-11-27
ATE358116T1 (de) 2007-04-15
US20040152779A1 (en) 2004-08-05
KR20020040900A (ko) 2002-05-30
HRP20040709A2 (en) 2004-12-31
BG106719A (bg) 2003-02-28
MXPA02003229A (es) 2002-09-30
AP2002002517A0 (en) 2002-06-30
IL149143A0 (en) 2002-11-10
EP1226110A1 (en) 2002-07-31
JP3632191B2 (ja) 2005-03-23
HK1049826B (zh) 2005-02-25
AP2004003186A0 (en) 2004-12-31
EP1506955B1 (en) 2007-03-28
AU2005201268A1 (en) 2005-04-21
HK1049826A1 (en) 2003-05-30
NZ517961A (en) 2002-12-20
KR100593349B1 (ko) 2006-06-26
JP2005036009A (ja) 2005-02-10
ES2282785T3 (es) 2007-10-16
PT1226110E (pt) 2005-07-29
CU23112A3 (es) 2006-02-27
BG108860A (en) 2006-03-31
SI1226110T1 (en) 2005-08-31
OA12070A (en) 2003-11-10
KR100566462B1 (ko) 2006-03-31
IS7497A (is) 2004-10-08
HRP20020428A2 (en) 2005-02-28
SV2001000188A (es) 2001-09-07
CZ295960B6 (cs) 2005-12-14
YU29302A (sh) 2005-06-10
KR20060013701A (ko) 2006-02-13
IL164060A0 (en) 2005-12-18
CA2386297C (en) 2010-02-09
AR026087A1 (es) 2002-12-26
IL149143A (en) 2007-02-11
NO20021780D0 (no) 2002-04-16
IS6348A (is) 2002-04-17
ECSP045393A (es) 2004-10-23
CA2386297A1 (en) 2001-04-26
HUP0203325A2 (hu) 2003-02-28
CZ20021310A3 (cs) 2003-05-14
DE60019628T2 (de) 2006-01-19
TR200500221T2 (tr) 2005-03-21
AU1092001A (en) 2001-04-30
AU778871B2 (en) 2004-12-23
MY127678A (en) 2006-12-29
ES2237464T3 (es) 2005-08-01
US6689906B1 (en) 2004-02-10
SK5232002A3 (en) 2003-07-01
UA72931C2 (uk) 2005-05-16
EA200200293A1 (ru) 2002-10-31
HUP0203325A3 (en) 2003-12-29
ATE293590T1 (de) 2005-05-15
US6835751B2 (en) 2004-12-28
BR0014972A (pt) 2002-07-16
EP1226110B1 (en) 2005-04-20
ZA200202543B (en) 2003-09-23
NO20043663L (no) 2002-04-16
GT200000183AA (es) 2005-06-17
TWI225855B (en) 2005-01-01
EA005206B1 (ru) 2004-12-30
HRP20020428B1 (en) 2006-02-28
NO20021780L (no) 2002-04-16
HN2000000224A (es) 2001-04-11
DOP2000000083A (es) 2002-03-30
EE200200211A (et) 2003-06-16
CO5280060A1 (es) 2003-05-30
WO2001028978A1 (en) 2001-04-26
CN1165518C (zh) 2004-09-08
DE60019628D1 (de) 2005-05-25
BR0014972B1 (pt) 2011-09-06
PE20010740A1 (es) 2001-07-27
GEP20043297B (en) 2004-01-12
GT200000183A (es) 2000-10-19
DE60034157D1 (de) 2007-05-10
CR6620A (es) 2004-02-02
EP1506955A1 (en) 2005-02-16
DE60034157T2 (de) 2007-12-13

Similar Documents

Publication Publication Date Title
HN2000000224A (es) Aminoacidos biciclicos como agentes farmaceuticos
HN2001000224A (es) Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
MX9701342A (es) Formulacion cosolvente de tirilazad para administracion parenteral.
AR032293A1 (es) Estuche farmaceutico
HN2003000407A (es) Nuevos derivados de fluoroglicosisdos aromaticos, medicamentos que contienen estos compuestos y sus usos.
AR033423A1 (es) Sales farmaceuticas constituidas de una sustancia activa farmaceutica y al menos un edulcorante, medicamentos que contienen estas sales y uso de estas sales para la preparacion de medicamentos
HN1998000115A (es) Formas de dosificación farmacéuticas sólidas
HN1999000066A (es) Formulaciones farmaceuticas
HN2001000037A (es) Derivados de eteres de pirazol como agentes antiinflamatorios/analgesicos
UY27455A1 (es) Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol -3-il)- sustituidos. su obtención y uso como fármacos.
CR7576A (es) Nuevas sales de perindopril y composiciones farmaceuticas que las contienen
ES2192234T3 (es) Composiciones farmaceuticas parenterales conteniendo sales de amonioalquilo de acidos 2-arilpropionicos.
PA8573101A1 (es) Tratamiento y prevencion de la osteoporosis
MX9503529A (es) Derivados de glicinamida, procedimiento para su preparacion y medicamentos que los contienen.
ATE541562T1 (de) Ibuprofen-suspension
HN2002000198A (es) Composiciones farmaceuticas de amlodipina y atorvastatina
ES2253378T3 (es) Extractos de espermatofitos con actividad antineoplasica.
PT1173434E (pt) Novo produto farmaceutico
UY26371A1 (es) Imidazo-3-il-aminas biciclicas, procedimiento para su preparacion y medicamentos que las contienen
UY25356A1 (es) Polisacaridos de sintesis,procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
MX9300399A (es) Derivados heterotriciclicos.
AR030503A1 (es) Antibioticos de cefalosporina y prodrogas de los mismos
HRP20080117A2 (en) Pharmaceutical composition for modified release insulin sensitiser
PE20021016A1 (es) Conjugados de pregabalina-lactosa
AR036689A1 (es) La forma pseudopolimorfica de (+/-) 1-(4-carbazoliloxi)-3-[2-(2-metoxifenoxi) etilamino]-2-propanol o formas opticamente activas o sales farmaceuticamente aceptables de la misma, uso de la misma, una composicion farmaceuticamente aceptable que la comprende, una forma de administracion farmaceuticame